Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Saved in:
Bibliographic Details
Title: Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Authors: Lim M; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA. mklim@stanford.edu., Ye X; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Piotrowski AF; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Desai A; Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ahluwalia MS; Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Walbert T; Department of Neurology, Henry Ford Health System, Detroit, MI, USA., Lesser G; Department of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA., Ellingson BM; Department of Radiology, Bioengineering, Psychiatry, and Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA., Peereboom DM; Department of Medicine, Cleveland Clinic, Cleveland, OH, USA., Fisher JD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Desideri S; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Jackson C; Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA., Pant A; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Jain A; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Verma R; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA., Oberlton B; Department of Immunology, Stanford University School of Medicine, Stanford, CA, USA., Piyadasa H; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Bettegowda C; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Engle L; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Taube J; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Bendall SC; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Choi J; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA., Drappatz J; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Lieberman FS; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Kleinberg LR; Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Pardoll DM; Department of Oncology and Medicine and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA., Nabors LB; Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA., Wen PY; Division of Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Grossman SA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Source: Nature medicine [Nat Med] 2026 Jul; Vol. 32 (7), pp. 2449-2460. Date of Electronic Publication: 2026 Jul 10.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-026-04475-7